Chardan initiates independent equity research coverage on StemCells

Nov 20 2010NewsGuard 100/100 Score

StemCells, Inc. (Nasdaq:STEM) announced today that Chardan Capital Markets (Chardan) initiated independent equity research coverage on the Company with a "Buy" recommendation and a 12-month price target of $1.45 per share. The new report, issued yesterday, was authored by Keay Nakae, Senior Analyst at Chardan. 

Chardan is the second firm to initiate independent equity research coverage of StemCells, Inc. this year. Headquartered in New York, Chardan is an investment banking and institutional brokerage firm with a focus on micro, small, and mid-cap markets. More information about Chardan is available at www.chardancm.com. StemCells does not endorse or adopt the reports, projections or statements of any analyst.

Source:

 StemCells, Inc.

Posted in:

Tags: , , , , , ,

Comments (0)

Suggested Reading

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration
Research suggests no need for yellow fever vaccine booster after initial dose
New research explores how antimicrobial exposure affects Parkinson’s disease risk
Can soda taxes fight obesity? New research adds to the debate
Research shows brain synchronization between humans and dogs
The potential to optimize laboratory testing and operations with automation and AI
Antibiotic activity altered by interaction with nanoplastics, new research shows
Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
(Logout)
Post

Newsletters you may be interested in

See all Newsletters »

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback

You might also like...
New research explores how omega-3 and omega-6 fatty acids may impact cancer rates